What the studies show
Nausea, diarrhoea and vomiting were the most frequent adverse events, mostly mild to moderate; discontinuation for adverse events 2.9% versus 0% in GLORY-2.
Several well-run randomised trials in people, pointing the same way. You can plan around this. It still says nothing about whether the effect is worth the side effects for you.
- 1Ji L, et al. Once-weekly mazdutide in Chinese adults with obesity or overweight (GLORY-1).N Engl J Med, 2025; DOI 10.1056/NEJMoa2411528610 adults, 48 weeks.
- 2Gao L, et al. Treatment with 9-mg mazdutide for weight reduction in Chinese adults with obesity: the GLORY-2 randomized clinical trial.JAMA, 2026;336:377–388461 adults, 60 weeks on 9 mg; −16.65% versus −1.50%.
In context
Mazdutide is a once-weekly GLP-1/glucagon dual agonist developed by Innovent with Lilly. In the 610-person GLORY-1 trial, published in the New England Journal of Medicine in May 2025, it produced 14.8% weight loss at 48 weeks on 6 mg against 0.5% on placebo; a 9 mg dose reached 16.7% at 60 weeks in the peer-reviewed GLORY-2 trial. China's regulator approved it for chronic weight management on 27 June 2025 and later for type 2 diabetes. It is not approved in the US, EU or UK.
Mazdutide is approved in china only. Legal status differs by country — see the regulation section or the jurisdiction pages.
Questions
Is Mazdutide proven to cause GI side effects?
What studies are behind the grade?
Is Mazdutide approved for this?
Other outcomes for Mazdutide
- ABody weight2 phase 3 RCTs
- BLiver fatPhase 3 sub-analyses
- ABlood glucose (HbA1c)DREAMS phase 3 programme
Written and maintained by LYO Research — how pages are written and checked. Reviewed 3 September 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →